ORIC Pharmaceuticals, Inc. (ORIC)
| Market Cap | 918.36M -25.5% |
| Revenue (ttm) | n/a |
| Net Income | -140.35M |
| EPS | -1.35 |
| Shares Out | 103.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 644,374 |
| Open | 9.32 |
| Previous Close | 9.34 |
| Day's Range | 8.69 - 9.34 |
| 52-Week Range | 7.23 - 14.68 |
| Beta | 1.21 |
| Analysts | Strong Buy |
| Price Target | 21.71 (+145.03%) |
| Est. Earnings | Nov 16, 2026 |
About ORIC
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutat... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for ORIC stock is "Strong Buy." The 12-month stock price target is $21.71, which is an increase of 145.03% from the latest price.
News
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing trea...
Oric Pharmaceuticals price target lowered to $14 from $17 at Wedbush
Wedbush lowered the firm’s price target on Oric Pharmaceuticals (ORIC) to $14 from $17 and keeps an Outperform rating on the shares. Relevant to Oric’s rinzimetostat, Johnson & Johnson (JNJ)…
Oric Pharmaceuticals selloff on J&J data ‘way overdone,’ says Cantor Fitzgerald
Oric Pharmaceuticals’ (ORIC) 30% selloff following J&J’s (JNJ) JNJ-6143 Phase 1 data appears “way” overdone, as safety and durability remain unproven despite encouraging efficacy, while rinzimetostat ...
Oric Pharmaceuticals selloff brings buying opportunity, says Jones
Jones views the selloff yesterday in shares of Oric Pharmaceuticals (ORIC) as a buying opportunity. Oric was under pressure on the back of Johnson & Johnson’s (JNJ) positive data with…
Oric Pharmaceuticals drops after J&J presents prostate cancer drug data
Shares of drug developer Oric Pharmaceuticals (ORIC) are falling after competitor Johnson & Johnson (JNJ) presented data about its own potential drug to treat patients with prostate cancer at a…
Oric Pharmaceuticals price target raised to $18 from $14 at Stifel
Stifel raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $18 from $14 and keeps a Buy rating on the shares.
Oric lung cancer data potentially best-in-class, says Jones
Jones keeps a Buy rating on Oric Pharmaceuticals (ORIC) with a $25 price target after the company announced Phase Ib data with enozertinib in front-line atypical EGFR mutated non-small cell…
ORIC Pharmaceuticals Transcript: Study update
In 26 treatment-naive patients, enozertinib showed 84% confirmed systemic ORR, 70% investigator-assessed CNS ORR and 88% 6-month landmark PFS, with 65% baseline brain metastases. REDWOOD-1 is planned for H1 2027.
ORIC Pharmaceuticals Press release: Study update
ORIC Pharmaceuticals issued a press release on October 23, 2026, disclosing material business information to investors.
Oric Pharmaceuticals presents enozertinib data at ESMO Congress
Oric Pharmaceuticals (ORIC) presented data for enozertinib in first-line NSCLC patients with EGFR atypical mutations at ESMO Congress 2026 and announced plans to advance enozertinib into a global Phas...
Oric Pharmaceuticals reports preclinical, translational rinzimetostat data
Oric Pharmaceuticals (ORIC) announced preclinical and translational data from an ePoster presentation at ESMO Congress 2026 highlighting the potential of rinzimetostat to enhance sensitivity to androg...
ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial
In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70%...
ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026
Preclinical data highlight potential advantages of targeting PRC2 via EED over EZH2, including the emergence of resistance mutations to EZH2 inhibitors like mevrometostat and against which the EED inh...
ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026
Conference call and webcast to take place on Friday, October 23, 2026, at 8:00 a.m. ET Event to feature Dr. Joshua Sabari to discuss enozertinib clinical data and the potential of enozertinib to treat...
Oric Pharmaceuticals price target raised to $26 from $23 at JPMorgan
JPMorgan raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $26 from $23 and keeps an Overweight rating on the shares after meeting with management. Enozertinib in epidermal growth…
Oric Pharmaceuticals participates in a conference call with JPMorgan
JPMorgan discusses Enozertinib, (formerly known as ORIC-114), with management on a conference call to be held on October 6 at 12 pm. Webcast Link
Oric Pharmaceuticals enters pact with Cancer Research UK to advance ORIC-259
Oric Pharmaceuticals (ORIC) announced an agreement with Cancer Research UK to advance a potential CIP2A-targeted therapy into clinical development. Under the agreement, Cancer Research UK’s Centre for...
ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target Cancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies...
Oric Pharmaceuticals initiated with an Outperform at Leerink
Leerink initiated coverage of Oric Pharmaceuticals (ORIC) with an Outperform rating and $26 price target
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address m...
Oric Pharmaceuticals initiated with a Buy at BTIG
BTIG analyst Jeet Mukherjee initiated coverage of Oric Pharmaceuticals (ORIC) with a Buy rating and $26 price target. Oric’s rinzimetostat has a potential best-in-class safety profile over Pfizer’s (P...
Oric Pharmaceuticals initiated with a Buy at BTIG
BTIG analyst Jeet Mukherjee initiated coverage of Oric Pharmaceuticals (ORIC) with a Buy rating and $26 price target
ORIC Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company is advancing two late-stage oncology programs: rinzimetostat for prostate cancer, with a phase III trial underway and strong safety differentiation, and enozertinib for lung cancer, targeting brain metastases with upcoming data at ESMO. Both programs address large markets, are well-funded through 2028, and have clear strategies for further development and potential partnerships.
ORIC Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Late-stage clinical programs focus on prostate and lung cancer, with HIMALAYA-1 phase III underway and additional studies planned. Positive readouts from Pfizer’s trials are expected to de-risk the PRC2 inhibitor class. Strong commercial potential and a cash runway into 2028 support ongoing development.
ORIC Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
Two late-stage oncology programs are advancing, with rinzimetastat in phase III for prostate cancer and enozertinib targeting lung cancer. Key differentiators include safety and potential resistance advantages, with major data readouts and program updates expected over the next 12–18 months.